Abstract #0909
Marker of disease progression in patients with relapsing remitting multiple sclerosis using 2D MRSI
Adriane Grger 1 , Vinzenz Fleischer 1 , Rupert Kolb 2 , Uwe Klose 2 , and Frauke Zipp 1
1
Department of Neurology and Neuroimaging
Center (NIC), Mainz, Germany,
2
Department
of Diagnostic and Interventional Neuroradiology,
Magnetic Resonance Research Group, Tbingen, Germany
Our findings of increased creatine and myo-inositol
levels but not different NAA levels suggest that
inflammation processes are more strongly associated with
early disease than neuronal loss that is correlated with
disease duration. Furthermore, the higher glutamate and
glutathione levels in RRMS patients receiving escalation
therapy (no alter metabolites pre to post treatment with
natalizumab) can be interpreted as a marker for more
fulminant disease progression but not for disease
duration.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
